Literature DB >> 16882600

Successful treatment of Sjogren's syndrome with rituximab.

Z Touma, J Sayad, T Arayssi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16882600     DOI： 10.1080/03009740500484056

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN： 0300-9742            Impact factor:   3.641


× No keyword cloud information.
  7 in total

Review 1.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

2.  The use of biological therapy in refractory rheumatic diseases other than rheumatoid arthritis: experience at a tertiary care center in Lebanon.

Authors:  Khaled M Musallam; Thurayya Arayssi; Ali T Taher; Nadim Kanj; Imad Uthman
Journal:  Rheumatol Int       Date:  2008-12-04       Impact factor: 2.631

Review 3.  Efficacy and safety of rituximab in rheumatic diseases.

Authors:  Eva Rath; Jochen Zwerina; Bastian Oppl; Valerie Nell-Duxneuner
Journal:  Wien Med Wochenschr       Date:  2015-01-21

4.  B-lymphocyte depletion ameliorates Sjögren's syndrome in Id3 knockout mice.

Authors:  Ikuko Hayakawa; Thomas F Tedder; Yuan Zhuang
Journal:  Immunology       Date:  2007-04-30       Impact factor: 7.397

5.  Renal involvement in primary Sjögren's syndrome: a clinicopathologic study.

Authors:  Saugar Maripuri; Joseph P Grande; Thomas G Osborn; Fernando C Fervenza; Eric L Matteson; James V Donadio; Marie C Hogan
Journal:  Clin J Am Soc Nephrol       Date:  2009-08-13       Impact factor: 8.237

6.  [Vasculitic leg ulcers in primary Sjogren syndrome].

Authors:  M Gwosdz; A Körber; U Hillen; J Dissemond
Journal:  Hautarzt       Date:  2008-05       Impact factor: 0.751

Review 7.  The potential utility of B cell-directed biologic therapy in autoimmune diseases.

Authors:  D G Arkfeld
Journal:  Rheumatol Int       Date:  2007-10-24       Impact factor: 2.631
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.